Broder; Cancer Act’s Special Authorities Don’t Give Director Immunity For NIH, HHS
In Brief: House, Senate Enact FY ’92 Budget Bills For NCI That Differ By $200 Million; Senate’s Is Higher
Bypass Budget Is Realistic, Defensible Plan, Broder Says
Broder On FDA: Don’t Blame Them For Doing Their Jobs (They Have To Work At Parklawn)
Tipping Resigned Forom ACS Following Volunteer Discontent
NSABP Sees Groups To Join Breast Cancer Prevention Trial
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program









